Research programme: anti-TNF monoclonal antibodies - Arana Therapeutics

Drug Profile

Research programme: anti-TNF monoclonal antibodies - Arana Therapeutics

Alternative Names: Anti-TNF monoclonal antibodies research programme - Arana Therapeutics; PN 0615

Latest Information Update: 02 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptech
  • Class Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 21 Aug 2009 This programme is in active development
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 19 Apr 2005 Preclinical trials in Rheumatoid arthritis in Australia (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top